{
    "nctId": "NCT05311397",
    "briefTitle": "A Study of A166 in Patients With Advanced Solid Malignant Tumors",
    "officialTitle": "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of A166 in Patients With Unresectable, Locally Advanced or Metastatic HER2-expressing Solid Tumors (KL166-I-01-CTP)",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign informed consent form;\n2. Age \u2265 18 years old, no gender limit;\n3. Patients had a histologically confirmed incurable locally advanced or metastatic solid tumors;\n4. Determined HER2-positive disease (detected by ISH or NGS) or HER2-expressing disease by evaluation or detection. Definition of HER2 expression in this study: Immunohistochemistry \\[IHC\\] \u2265 1\uff0b;\n5. Patients unable to benefit from the available standard treatment according to the judgment of the investigator;\n6. White blood cell count (WBC) \u2265 4.0\u00d7109/L or \u2265 lower limit of normal value; Neutrophil count (NEUT) \u2265 1.5\u00d7109/L; Platelet count (PLT) \u2265 100\u00d7109/L; Hemoglobin concentration \u2265 9.0 g/dL;\n7. Total bilirubin (TBIL) \u2264 1.5\u00d7ULN. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase \u2264 2.5 times the upper limit of normal (ULN). For patients with liver metastases, ALT and AST \u2264 5 times ULN, and for patients with liver and/or bone metastases, alkaline phosphatase \u2264 5 times ULN;\n8. Creatinine clearance rate \u2265 50 ml/min;\n9. Patients had an Eastern Cooperative Oncology Group (ECOG)performance status of 0 or 1, the expected survival time is \u2265 3 months;\n10. During the study period and within 7 months after the final administration of A166, patients with fertility (regardless of male and female) must receive effective medical contraceptive measures;\n11. The patients must recover from all acute toxicities of the previous treatment (relieved to grade 1 or baseline), except for hair loss and vitiligo;\n\nExclusion Criteria:\n\n1. Severe or uncontrollable heart disease requiring treatment, or grade 3 or 4 congestive heart failure according to the New York Society of Cardiology (NYHA), or unstable angina pectoris that cannot be controlled by drugs, or history of myocardial infarction within 6 months prior to enrollment, or severe arrhythmia requiring medical treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia);\n2. History of \u2265 Grade 3 allergic reaction to trastuzumab;\n3. Permanent with drawal of trastuzumab due to any previous toxicity;\n4. Patients with brain metastases who have symptoms or who have received the radiotherapy or surgery within 3 months before the first administration;\n5. Patients requiring oxygen therapy in daily activities;\n6. Grade 2 or higher peripheral neuropathy;\n7. Any chemotherapy, hormone therapy (except dexamethasone), radiotherapy, immunotherapy or biological therapy received within 4 weeks before the first administration;\n8. Prior-treatment with other clinical research drugs within 4 weeks before the first administration;\n9. Patients who have undergone major surgery within 4 weeks before the first administration;\n10. Active hepatitis B (hepatitis B surface antigen positive and HBV-DNA higher than the upper limit of reference value) or hepatitis C (positive hepatitis C virus antibody and HCV-RNA higher than the upper limit of reference value); current or past alcoholics ; Liver cirrhosis;\n11. Known active human immunodeficiency virus (HIV);\n12. Systemic diseases that cannot be controlled, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, glaucoma, etc according to investigator's judgment;\n13. Current pregnancy or lactation;\n14. QTc interval\\> 470 ms according to the baseline measurement:;\n15. Left ventricular ejection fraction (LVEF) \\<45% according to the echocardiogram (ECHO) or multi-gate circuit controlled acquisition (MUGA) ;\n16. Previous cumulative doxorubicin accumulation \\> 360 mg/m2 or its equivalent dose;",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}